

# Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

NCT06546423

---

Status	RECRUITING
Phase	Phase 1
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	25 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- e24months of age and \<60 months of age at the time of inoculation
  - HAI Screening for HPIV3-neutralizing antibody is obtained within the calendar year of inoculation
  - Seropositive for HPIV3 antibody, defined as serum HPIV3 HAI titer \>1:8
  - Pre-inoculation serum sample for HPIV3-neutralizing antibody specimen is obtained no more than 42 days prior to inoculation
  - In good health based on review of the medical record, history, and physical examination at the time of inoculation
- ... and 4 more (see full listing online)

### Exclusion (48)

- \<24 months of age and \>60 months of age at the time of inoculation.
  - Born at less than 34 weeks gestation
  - Maternal history of a positive HIV test before or during pregnancy.
  - Evidence of chronic disease
  - Known or suspected infection or impairment of immunological functions
- ... and 43 more (see full listing online)

## Locations (4 total)

---

CIR - Rangos, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States  
CIR South, Columbia, Maryland, United States  
University of Rochester Medical Center, Rochester, New York, United States  
... and 1 more locations